NZ613713A - Fviii-derived peptides - Google Patents

Fviii-derived peptides

Info

Publication number
NZ613713A
NZ613713A NZ613713A NZ61371310A NZ613713A NZ 613713 A NZ613713 A NZ 613713A NZ 613713 A NZ613713 A NZ 613713A NZ 61371310 A NZ61371310 A NZ 61371310A NZ 613713 A NZ613713 A NZ 613713A
Authority
NZ
New Zealand
Prior art keywords
fviii
derived peptides
peptide
haemophilia
suppression
Prior art date
Application number
NZ613713A
Other languages
English (en)
Inventor
David Wraith
Original Assignee
Apitope Int Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40834163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ613713(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apitope Int Nv filed Critical Apitope Int Nv
Publication of NZ613713A publication Critical patent/NZ613713A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ613713A 2009-05-18 2010-05-17 Fviii-derived peptides NZ613713A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0908515.0A GB0908515D0 (en) 2009-05-18 2009-05-18 Peptide
NZ596300A NZ596300A (en) 2009-05-18 2010-05-17 Fviii-derived peptides

Publications (1)

Publication Number Publication Date
NZ613713A true NZ613713A (en) 2014-10-31

Family

ID=40834163

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ613713A NZ613713A (en) 2009-05-18 2010-05-17 Fviii-derived peptides
NZ596300A NZ596300A (en) 2009-05-18 2010-05-17 Fviii-derived peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ596300A NZ596300A (en) 2009-05-18 2010-05-17 Fviii-derived peptides

Country Status (30)

Country Link
US (1) US8703705B2 (enExample)
EP (2) EP2465523B1 (enExample)
JP (1) JP5784009B2 (enExample)
KR (1) KR101673889B1 (enExample)
CN (1) CN102458445B (enExample)
AU (1) AU2010250957B2 (enExample)
BR (1) BRPI1012845A2 (enExample)
CA (1) CA2762020C (enExample)
CL (1) CL2011002893A1 (enExample)
CO (1) CO6460780A2 (enExample)
CY (1) CY1115832T1 (enExample)
DK (1) DK2465523T3 (enExample)
EA (1) EA027229B1 (enExample)
EC (1) ECSP11011540A (enExample)
ES (1) ES2525448T3 (enExample)
GB (1) GB0908515D0 (enExample)
HR (1) HRP20141182T1 (enExample)
IL (1) IL216199A (enExample)
MX (1) MX2011012270A (enExample)
MY (1) MY168207A (enExample)
NZ (2) NZ613713A (enExample)
PL (1) PL2465523T3 (enExample)
PT (1) PT2465523E (enExample)
RS (1) RS53671B1 (enExample)
SG (2) SG190573A1 (enExample)
SI (1) SI2465523T1 (enExample)
SM (1) SMT201400186B (enExample)
UA (1) UA110921C2 (enExample)
WO (1) WO2010133834A2 (enExample)
ZA (1) ZA201108446B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353233B (es) 2009-12-06 2018-01-08 Bioverativ Therapeutics Inc Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1311542T1 (sl) 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
JP2005538694A (ja) * 2002-04-18 2005-12-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 修飾されたviii因子
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII

Also Published As

Publication number Publication date
KR101673889B1 (ko) 2016-11-08
SMT201400186B (it) 2015-01-15
GB0908515D0 (en) 2009-06-24
CA2762020A1 (en) 2010-11-25
CA2762020C (en) 2018-08-28
CN102458445B (zh) 2014-06-11
SI2465523T1 (sl) 2015-02-27
IL216199A0 (en) 2012-01-31
MX2011012270A (es) 2011-12-12
KR20120023023A (ko) 2012-03-12
WO2010133834A3 (en) 2011-02-24
WO2010133834A2 (en) 2010-11-25
US20120121625A1 (en) 2012-05-17
EP2465523B1 (en) 2014-10-01
CL2011002893A1 (es) 2012-08-17
JP5784009B2 (ja) 2015-09-24
HK1173358A1 (en) 2013-05-16
SG176138A1 (en) 2011-12-29
EP2432494A2 (en) 2012-03-28
JP2012527440A (ja) 2012-11-08
HRP20141182T1 (hr) 2015-02-13
DK2465523T3 (en) 2014-12-15
PT2465523E (pt) 2014-12-09
SG190573A1 (en) 2013-06-28
US8703705B2 (en) 2014-04-22
NZ596300A (en) 2013-08-30
UA110921C2 (uk) 2016-03-10
EA201171430A1 (ru) 2012-05-30
BRPI1012845A2 (pt) 2016-10-11
CO6460780A2 (es) 2012-06-15
AU2010250957A1 (en) 2011-12-01
EP2465523A1 (en) 2012-06-20
RS53671B1 (sr) 2015-04-30
ECSP11011540A (es) 2012-01-31
AU2010250957B2 (en) 2015-01-15
ES2525448T3 (es) 2014-12-23
IL216199A (en) 2015-11-30
EA027229B1 (ru) 2017-07-31
PL2465523T3 (pl) 2015-03-31
CY1115832T1 (el) 2017-01-25
ZA201108446B (en) 2013-01-30
CN102458445A (zh) 2012-05-16
MY168207A (en) 2018-10-15

Similar Documents

Publication Publication Date Title
MY153116A (en) Smac mimetic
MX2012009748A (es) USO DE PEPTIDOS INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMANTE-BETA1(TGF-ß1) PARA EL TRATAMIENTO DE FIBROSIS Y/U OPACIDAD CORNEAL.
NZ613713A (en) Fviii-derived peptides
TN2012000303A1 (en) Oxyntomodulin peptide analogue
SMT202000407T1 (it) Peptidi inibitori derivati da trascritto 1 trem-like (tlt-1) e relativi usi
IL211930A (en) Peptides and nonsense for their use in preventing cell adhesion
EP2442829A4 (en) Structured viral peptide compositions and methods of use
TN2012000302A1 (en) Oxyntomodulin peptide analogue
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
AU333421S (en) Showerhead
WO2008059252A3 (en) Methods and composition fro t cell receptors which recognize 5t4 antigen
WO2012129427A3 (en) Aromatic-cationic peptides and uses of same
BRPI1009716A2 (pt) ligações péptidicas de quemoquina, capazes de inibir o curso da autoimunidade, inflamação e câncer
NZ588200A (en) Procoagulant peptides
WO2009052489A3 (en) Novel inhibitors of mammalian tight junction opening
PL2588491T3 (pl) Nowy peptyd i jego zastosowanie
EP2074138A4 (en) NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF
NZ749998A (en) Tfpi inhibitors and methods of use
PL2421884T3 (pl) Aktywatory proteasomowe w formie hydrolizatu peptydowego i zawierające je kompozycje
PL2441774T3 (pl) Peptydy zawierające motywy palców cynkowych i ich zastosowania
MX2011008179A (es) Peptidos para vacuna.
AU2011259204A1 (en) Antigen peptide and use thereof
ZA201101508B (en) Novel melanoma antigen peptide and uses thereof
WO2009095646A3 (en) Peptides from factor viii
WO2008128064A9 (en) Truncated analogs of peptide and polypeptide therapeutics

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 MAY 2017 BY AJ PARK

Effective date: 20150311

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2018 BY CPA GLOBAL

Effective date: 20170331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2019 BY CPA GLOBAL

Effective date: 20180405

LAPS Patent lapsed